PDF(Pubmed)
Abstract：
Janus kinase (JAK) inhibitors are novel molecules increasingly prescribed for various dermatologic conditions. However, the Food and Drug Administration recently reported increased risks of malignancy in patients taking this class of medication. To shed more light on this potential adverse effect, we present a patient with cutaneous T-cell lymphoma possibly associated with his treatment with a JAK inhibitor for atopic dermatitis. To our knowledge, there are no reported cases of cutaneous T-cell lymphoma in association with JAK inhibitors in the literature. We highlight the importance of remaining cautious when prescribing this new class of medication, especially in patients with risk factors for malignancy. Moreover, when faced with atypical presentations of atopic dermatitis, we stress the need for a biopsy to make the correct diagnosis prior to treatment. Lastly, we encourage further studies to better characterize the malignancy risk associated with JAK inhibitors.
摘要：
Janus激酶（JAK）抑制剂是越来越多地用于各种皮肤病的新型分子。然而,美国食品和药物管理局最近报告说，服用此类药物的患者患恶性肿瘤的风险增加。为了进一步揭示这种潜在的不利影响，我们介绍了1例皮肤T细胞淋巴瘤患者,可能与他使用JAK抑制剂治疗特应性皮炎有关.据我们所知,文献中没有报道与JAK抑制剂相关的皮肤T细胞淋巴瘤病例.我们强调在开这种新型药物时保持谨慎的重要性，尤其是有恶性肿瘤危险因素的患者。此外，当面对特应性皮炎的非典型表现时，我们强调需要在治疗前进行活检以做出正确的诊断。最后,我们鼓励进一步研究以更好地表征与JAK抑制剂相关的恶性肿瘤风险.
